Gastroenterology

Fixes the window in which a blood test could plausibly work and shows why CA 19-9 alone is not enough: half of early cases are missed even at diagnosis, and Lewis-negative patients are missed entirely.

PRECEDE is the infrastructure answer to CAPS's problem: no single centre can enrol enough high-risk people to validate an early detection test.

Exosome DNA adds signal where free DNA is scarce, particularly after neoadjuvant treatment, and the two together give the strongest published blood-based prognosis in this disease.

A cancer next to a cyst is not necessarily from the cyst, so removing the cyst does not always remove the risk, and surveillance must cover the whole gland.

It fixed the working numbers for a comprehensive panel in pancreatic cancer: a hit worth acting on in about one patient in six, most of it in repair genes and the KRAS wild-type minority.

A scoring tool that needs no new test and can run in primary care records; it turns the 1 percent of Chari's cohort into a 3.6 percent group in whom imaging or a blood test becomes defensible.

The first long-term evidence that surveillance in high-risk people finds operable cancers, and the source of the imaging features that trigger surgery in the CAPS recommendations.

It made subtyping possible on the archived tissue every hospital has, and it retired one of the four Bailey subtypes.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

The evidence that molecular cyst-fluid testing can spare operations, now part of specialist practice although not a universal standard.

It fixes the order of events, with the initiating mutation present in the smallest visible lesion, and it warns that finding mutant KRAS in a duct does not mean cancer.

The observation behind every new-onset diabetes strategy: a 1 percent prevalence is a hundred times the general population's and high enough for a blood test or scan to have a useful positive predictive value.

The origin of the 10 to 15 year window quoted for gallbladder carcinogenesis, which is the argument that cholecystectomy for stones or dysplasia in high-incidence regions prevents cancer years later.

Fixes the window in which a blood test could plausibly work and shows why CA 19-9 alone is not enough: half of early cases are missed even at diagnosis, and Lewis-negative patients are missed entirely.

PRECEDE is the infrastructure answer to CAPS's problem: no single centre can enrol enough high-risk people to validate an early detection test.

Exosome DNA adds signal where free DNA is scarce, particularly after neoadjuvant treatment, and the two together give the strongest published blood-based prognosis in this disease.

A cancer next to a cyst is not necessarily from the cyst, so removing the cyst does not always remove the risk, and surveillance must cover the whole gland.

It fixed the working numbers for a comprehensive panel in pancreatic cancer: a hit worth acting on in about one patient in six, most of it in repair genes and the KRAS wild-type minority.

A scoring tool that needs no new test and can run in primary care records; it turns the 1 percent of Chari's cohort into a 3.6 percent group in whom imaging or a blood test becomes defensible.

The first long-term evidence that surveillance in high-risk people finds operable cancers, and the source of the imaging features that trigger surgery in the CAPS recommendations.

It made subtyping possible on the archived tissue every hospital has, and it retired one of the four Bailey subtypes.

The evidence that molecular cyst-fluid testing can spare operations, now part of specialist practice although not a universal standard.

It fixes the order of events, with the initiating mutation present in the smallest visible lesion, and it warns that finding mutant KRAS in a duct does not mean cancer.

The observation behind every new-onset diabetes strategy: a 1 percent prevalence is a hundred times the general population's and high enough for a blood test or scan to have a useful positive predictive value.